AZN Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£104.74 |
| 52 Week High | UK£133.88 |
| 52 Week Low | UK£94.61 |
| Beta | 0.18 |
| 11 Month Change | -9.75% |
| 3 Month Change | -19.90% |
| 1 Year Change | 2.89% |
| 33 Year Change | 24.53% |
| 5 Year Change | 40.44% |
| Change since IPO | 1,477.41% |
Recent News & Updates
Shareholder Returns
| AZN | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 5.0% | 4.5% | 2.2% |
| 1Y | 2.9% | 0.7% | 8.0% |
Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: AZN underperformed the UK Market which returned 8% over the past year.
Price Volatility
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AZN has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 89,900 | Pascal Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
AstraZeneca PLC Fundamentals Summary
| AZN fundamental statistics | |
|---|---|
| Market cap | UK£162.38b |
| Earnings (TTM) | UK£5.18b |
| Revenue (TTM) | UK£40.86b |
31.3x
P/E Ratio4.0x
P/S RatioIs AZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZN income statement (TTM) | |
|---|---|
| Revenue | US$51.21b |
| Cost of Revenue | US$8.91b |
| Gross Profit | US$42.30b |
| Other Expenses | US$35.80b |
| Earnings | US$6.50b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 4.19 |
| Gross Margin | 82.61% |
| Net Profit Margin | 12.68% |
| Debt/Equity Ratio | 74.0% |
How did AZN perform over the long term?
See historical performance and comparison